Trial · NCT06313996
A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
NCT06313996, Phase 3, Withdrawn, Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
3 sourcestrials-2026-11-12-0.5.0
Cite this record
ConductScience Library. A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma. Trials, record NCT06313996. Release trials-2026-11-12-0.5.0, 12 Nov 2026. https://conductscience.org/library/trials/NCT06313996
On this page
Trial
As registered on ClinicalTrials.gov, in the graph's capture of the registry.
- Title
- A Study to Evaluate the Efficacy and Safety of Liso-cel Compared to Standard of Care in Adults With Relapsed or Refractory Follicular Lymphoma
- NCT number
- NCT06313996
- Status
- Withdrawn
- Phases
- Phase 3
- Enrollment
- 0 participants, actual
- Lead sponsor
- Juno Therapeutics, Inc., a Bristol-Myers Squibb Company
- Conditions
- Relapsed or Refractory Follicular Lymphoma
- Interventions
- Cyclophosphamide, Doxorubicin, Vincristine, Rituximab, Prednisone, Bendamustine, Lenalidomide, Fludarabine, Liso-cel
- First posted
- 2024-03-15
- Last updated
- 2026-03-18
Source ClinicalTrials.gov
Registered outcomes20
Each outcome the trial registered, primary first, in ClinicalTrials.gov's words.
| List | Outcome | Time frame | Description |
|---|---|---|---|
| Primary | Progression-free survival (PFS) | Up to 5 years from the last participant randomized | Defined as the time from randomization to death due to any cause or progressive disease (PD) per independent review committee (IRC) assessment using the Lugano 2014 Criteria, whichever occurs first |
| Secondary | Complete response (CR) | Up to 5 years from the last participant randomized | Defined as participants achieving a complete response per IRC assessment using the Lugano 2014 Criteria |
| Secondary | Overall survival (OS) | Up to approximately 7 years | Defined as the time from randomization to death due to any cause |
| Secondary | Overall response (OR) | Up to 5 years from the last participant randomized | Defined as participants achieving a response (CR or partial response (PR)) per IRC assessment using the Lugano 2014 Criteria |
| Secondary | Duration of response (DOR) | Up to 5 years from the last participant randomized | Defined as the time from first response (CR or PR) per IRC assessment using the Lugano 2014 Criteria to PD or death due to any cause, whichever occurs first |
| Secondary | Event-free survival (EFS) | Up to 5 years from the last participant randomized | Defined as the time from randomization to the first documentation of progressive disease (PD) per IRC assessed using the Lugano 2014 Criteria start of new anti-cancer therapy, or death due to any cause, whichever occurs first |
| Secondary | Time to next anti-cancer therapy (TTNLT) | Up to 5 years from the last participant randomized | Defined as time from randomization to start of new anti-cancer therapy or death due to any cause, whichever occurs first |
| Secondary | PFS rate | Up to 5 years from the last participant randomized | |
| Secondary | EFS rate | Up to 5 years from the last participant randomized | |
| Secondary | OS rate | Up to approximately 7 years |
1 to 10 of 20Source ClinicalTrials.gov
See all 20 registered outcomesOutcomes0
Each outcome the trial posted results for, in ClinicalTrials.gov's words.
None in this release.
Results by group0
Each measurement the trial posted, group by group, in the words and numbers it posted.
None in this release.
Participant flow0
How many started, completed or left each group, period by period.
None in this release.
Adverse events0
Each adverse event the trial posted, group by group: the participants affected out of those at risk.
None in this release.
Adverse event totals0
The totals the trial posted for each group.
None in this release.
Papers0
The papers the trial lists on ClinicalTrials.gov.
None in this release.
Grants0
The grants NIH RePORTER links to the trial, newest funded first: NIH's, and some of AHRQ's, CDC's, FDA's and VA's. Each shows its title, principal investigators, organization and funder in its newest year.
None in this release.
Trial comparisons0
Comparisons of the trial's two groups, calculated by ConductScience from the counts it posted.
None in this release.
Tests0
The ConductCognition tests this trial's registered outcomes name, as ScienceGraph matched them in trial-tests-2026-11-12-0.2.1.
None in this release.
Data dates
The day each source was copied for this release.
Sources 3
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ClinicalTrials.govNo license stated
- NIH RePORTER's clinical studies and project filesPublic domain
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ClinicalTrials.govnone stated
- NIH RePORTER's clinical studies and project filesPublic domain (NIH RePORTER)
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this trial from software.
The record and each of its lists are JSON, twenty rows a page. No key.
GET https://conductscience.org/api/trials/v1/NCT06313996
GET https://conductscience.org/api/trials/v1/NCT06313996/registered